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1. Introduction 
Free peritoneal mast cells of the rat are used as a 
model for the study of secretion. Adenosine 3’: 5’ 
cyclic monophosphate itself has no effect on the 
secretion of histamine from mast cells, presumably 
because it cannot pass across the membrane into the 
cell. UsingN602’-dibutyryl 3’: 5’ cyclic adenosine 
monophosphate which can penetrate into cells, and 
other agents which cause a rise in the intracellular 
level of 3’: 5’ cyclic adenosine monophosphate 
(cyclic AMP), it has been shown that intracellular 
cyclic AMP is able to exert an inhibitory effect on 
the secretion of histamine-containing granules from 
mast cells [l--4]. The inhibitory action of cyclic 
AMP appears to be the result of inhibition of the 
influx of calcium into mast cells [5,6], which is the 
initial and essential step in the secretory process of 
these cells [7]. 
In contrast to the action of cyclic AMP, it has been 
reported that 8-bromo cyclic guanosine monophos- 
phate enhances the secretory response of mast cells 
in human lung [8]. 
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We show here that adenosine 3’: 5’ cyclic phos- 
phorothioate has an action on histamine secretion 
similar to that of dibutyryl cyclic AMP, and so it 
follows that intracellular cyclic AMP, rather than 
free butyric acid which may be formed from dibutyryl 
cyclic AMP, inhibits the secretion of histamine. Gua- 
nosine 3’: 5’ cyclic phosphorothioate was also found 
to inhibit histamine secretion. 
2. Methods 
‘Ihe source and preparati?n of rat peritoneal mast 
cells has been described [9 1. Aliquots of cells were 
incubated in a medium based on Tyrode solution in 
which bicarbonate-CO* buffer was replaced by 
Hepes [9]. Histamine was assayed fluorimetrically 
[lo] and for each aliquot of cells, both the histamine 
released into the incubating medium and that remain- 
ing in the cell pellet was determined so that for each 
sample the percentage of histamine released from the 
cells could be calculated as shown: 
Amount of histamine in supernatant 
x 100% 
Amount in supernatant t amount in pellet 
N602’-dibutyryl 3’: 5’ cyclic adenosine monophos- 
phate (db CAMP) was obtained from Sigma Chemical 
Esevier/North-Holland Biomedical Press 
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Co., London. Adenosine and guanosine 3’: 5’ cyclic 
phosphorothioates were synthesized as in [ 111. The 
ionophore A23 187 (Eli Lily) was first dissolved in 
ethanol and then diluted into physiological saline 
before addition to the cells: the final concentration 
of ethanol being too small to affect the response of 
the cells to antigen stimulation. 
3. Results and discussion 
Adenosine 3’: 5’ cyclic phosphoro~ioate produced 
a concentration-dependent inhibition of histamine 
secretion induced by antigen stimulation. A compar- 
ison of the activity of N6Q2’-dibutyryl 3’: 5’ cyclic 
adenosine monophosphate with that of adenosine 
3’: 5’ cyclic phosphorothioate was made using a 2+2 
biological assay design. Cells were preincubated with 
the compounds for 10 min before antigen stimulation 
since preliminary experiments showed that there was 
no increase in the inhibitory effect with preincubation 
over the period IO-30 min. The results depicted in 
fig.1 are the means from 3 experiments in which 2 
concentrations of each compound were used to inhibit 
histamine secretion. In each experiment, a particular 
concentration was tested on quadruplicate samples 
of cells. No difference in activity between dibutyryl 
cyclic AMP and adenosine cyclic phosphorothioate 
was observed. An analysis of variance was carried out 
on the results of these experiments and it was deter- 
mined that differences between the 2 compounds as 
large or larger than those observed would be common 
on a chance basis (P > 0.05). The analysis of variance 
i 
I 1 
0.1 1.0 
CONCENTRATION OF NUCLEOTIDE 
Im-mole/l. 1 
Fig. 1. Concentration-response relationships for the inhibition 
of antigen-induced histamine secretion by N*0”dibutyryl 
3’: 5’ cyclic adenosine ~onophosphate (0 -0) and adenosine 
3’: 5’ cyclic phosphorothioate (* -0). Each point is the 
mean of quadruplicate determinations in each of 3 separate 
experiments. Histamine secretion i  the absence of inhibitor 
ranged from 7-33% total. 
Table 1 
Inhibition by dibutyryl cyclic AMP (db CAMP) and adenosine cyclic phosphorothioate 
(CAMPS) of histamine secretion induced by antigen (Ag) or A23187 (0.6 rmol/l) 
Inhibition (%) 
Exp. a Exp. b Exp. c Mean 
Release by Ag A23187 Ag A23187 Ag A23187 Ag A23187 
dbcAMP 0.3 - - 28 8 42 5 35 6 
mmol/l 1.0 71 15 6218 -- 66 16 
CAMPS 0.3 - - 24 5 21 0 23 3 
mmol/l 1.0 60 18 - - 38 0 49 9 
Control 
secretion (%) 37 81 44 77 58 42 
- 
Inhibition is expressed as % histamine release in the absence of nucleotide (control). Each 
value is a mean of duplicate determ~ations 
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provided no evidence against the hypothesis that the 
concentration-response lines are parallel, and it 
rejected the null hypothesis that the gradient of the 
concentration-response lines is zero. 
It has previously been reported that dibutyryl 
cyclic AMP inhibits antigen-induced histamine release 
but has no effect on histamine release induced by the 
ionophore A23187 [5] . Table 1 shows that both 
dibutyryl cyclic AMP and adenosine cyclic phos- 
phorothioate produce a marked, dose-related inhibi- 
tion of antigen-stimulated histamine secretion whilst 
having little or no effect on the secretion induced by 
the calcium inophore A23187. Again, cells were pre- 
incubated for 10 min with the nucleotide before addi- 
tion of the histamine releasing stimulus. 
Table 2 demonstrates that guanosine 3’: 5’ cyclic 
phosphorothioate produces a concentration-dependent 
inhibition of antigen stimulated histamine secretion. 
Cells were preincubated with the nucleotide for 10 
min before stimulation. Concentrations down to 
0.1 pmol/l were tested but only those in the range 
0.01-l .O mmol/l produce an effect on histamine 
secretion. 
The nucleoside cyclic phosphorothioates were syn- 
thesized to obtain analogues of such cyclic phosphates 
which would not be hydrolysed readily by phospho- 
diesterase and which might be able to enter the cell. 
Although the dibutyryl derivatives of the cyclic nucleo- 
tides have these properties, alternative analogues were 
thought to be desirable because of the reported side- 
Table 2 
Inhibition by guanosine 3’: 5’ cyclic phosphorothioatc of 
antigen-induced histamine sccrction 
__- ______ 
Nucleotide Fsperiment 
(nunol/l) 
a b c 
____~~ 
0.01 12 
0.1 26 54 27 
1.0 40 
Control 
secretion (c/c) 12 12 36 
Inhibition is cxprcssod as % secretion in the absence of nuclco- 
tide (control). Each value is a mean of duplicate determinations 
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effects of butyric acid [ 12-141. The adenosine cyclic 
phosphorothioate has been shown to activate protein 
kinase, to be hydrolysed by phosphodiesterase although 
considerably more slowly than cyclic AMP [ 1 l] and 
to mediate cell aggregation in Dictyosteliutn dis- 
coideurn [ 151. It also mimics the action of dibutyryl 
cyclic AMP on amylase secretion from rat parotid 
slices [ 161. This is probably an indication of sufficient 
lipid solubility of this compound to allow its entry 
into cells. We show here that in the process ofhistamine 
secretion from rat mast cells, adenosine 3’: 5’ cyclic 
phosphorothioate has an activity which is indistin- 
guishable from that of N’@‘-dibutyryl 3’: 5’ cyclic 
adenosine monophosphate. The inhibition of secretion 
produced by these agents is thought to result from an 
increase in intracellular 3’: 5’ cyclic adenosine mono- 
phosphate level. 
Adenosine cyclic phosphorothioate inhibits hista- 
mine secretion induced by antigen and has little if 
any inhibitory effect on secretion induced by the cal- 
cium ionophore A23 187. A similar action has already 
been reported for dibutyryi cyclic AMP [5] and since 
the ionophore and antigen are thought to initiate 
release by increasing membrane permeability to cal- 
cium and allowing calcium to enter the mast cell [6,7], 
it follows that adenosine cyclic phosphorothioate and 
dibutyryl cyclic adenosine monophosphate selectively 
inhibit antigen-induced histamine release by interfering 
with calcium transport into mast cells mediated by 
the antigen stimulus. It has been shown that dibutyryl 
adenosine cyclic monophosphate inhibits antigen- 
induced calcium-45 uptake but not A23 i 87-induced 
calcium-45 uptake in mast cells [6] . 
Guanosine cyclic phosphorothioate inhibits hista- 
mine secretion induced by antigen whereas it has been 
found that 8-bromo cyclic guanosine monophosphate 
enhanced histamine release induced by antigen from 
human lung mast cells [8]. S-Bromo and dibutyryl 
cyclic guanosine monophosphate are both without 
effect on rat mast cells at concentrations up to 
1 mmole/l (J. C. F., unpublished data). The basis for 
these differences. and the mechanism of action of 
guanosine cyclic phosphorothioate in inhibiting hist- 
amine secretion remains to be determined. 
The nucleoside cyclic phosphorothioates are valuable 
new probes of cyclic nucleotide effects and should 
help to assess the role of cyclic nucleotides in secre- 
tion and other biochemical processes. 
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